Introduction The capacity to translate basic research discoveries into clinical applications and to synthesize, disseminate, and integrate clinical research results into practice remains challenging. To help innovate the means of communicating and disseminating knowledge between actors across the research-to-practice continuum, this study aims to identify barriers and enablers in building and implementing a collaborative platform that will bring together all the actors involved. Methods The study was conducted based on a qualitative descriptive design and a deductive thematic analysis. Recruitment was performed using a purposive sampling strategy. Data were collected through three focus groups with a total of 23 participants involving actors from each pillar of the research-to-practice continuum: eight basic researchers (Group 1), eight clinical and organizational researchers (Group 2), and seven knowledge users, including healthcare professionals and patient partners (Group 3). Results Few participants had concrete experience in the field of translational research, but half of them had already collaborated with actors from other research pillars. Identified barriers (e.g., length and complexity of the process, differences in knowledge and professional goals between clinical and basic research, insufficient resources and time to invest in research projects, lack of recognition of the added value of patient implication) and enablers (e.g., use of clear guidelines and targeted research questions, networking by matching according to area of practice and interests, introduction to research in the curriculum of medical students, dissemination of scientific information in a language understandable to all) emerging from the focus groups were clustered into four main categories: (i) translational research project concretization, (ii) basic research applicability, (iii) clinician availability and commitment, and (iv) patient involvement and recruitment. These barriers and enablers emphasized the need to decomplexify the translational research process for all actors involved in the research-to-practice continuum. They also accentuated the need to recognize the social responsibility of basic research and increase its impact on the ground, intensify the exposure of medical students to research and value clinicians' involvement in research activities, and engage patients as research partners to help prioritize research topics and communicate science comprehensibly. The success indicators of the main platform would be the relevance, strength, and duration of collaborations, the number of projects implemented and completed, and the grants and funding obtained. Conclusion We identified key barriers and enablers to implement a functional and dynamic collaborative platform. Participants' desire to collaborate combined with the absence of a tool to foster efficient collaborations are indicators of the importance of our approach. Creating a readily accessible collaborative platform to all actors across the research-to-practice continuum has the potential to drive research advances based on the needs of patients, clinicians, and the public, and thus facilitate their clinical application in a timelier manner to improve healthcare standards and services as well as population health outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890498 | PMC |
http://dx.doi.org/10.7759/cureus.78699 | DOI Listing |
BMJ Open
March 2025
Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford Nuffield, Oxford, UK
Introduction: Gender-affirming care (GAC) includes interventions aimed at supporting an individual's gender identity. Canada is experiencing an increase in referrals for GAC, higher than any other health service; therefore, there is a need for a systematic approach to health outcome measurement to effectively evaluate care. This review aims to analyse health outcome measurement in Canadian GAC, focusing on what is measured, how it is measured and associated barriers and enablers.
View Article and Find Full Text PDFGastroenterology
March 2025
APC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland.
Inflammatory bowel disease (IBD) is marked by significant clinical heterogeneity, posing challenges for accurate diagnosis and personalized treatment strategies. Conventional approaches, such as endoscopy and histology, often fail to adequately and accurately predict medium and long-term outcomes, leading to suboptimal patient management. Artificial intelligence (AI) is emerging as a transformative force enabling standardized, accurate, and timely disease assessment and outcome prediction, including therapeutic response.
View Article and Find Full Text PDFInt J Biol Macromol
March 2025
Department of Orthopedics, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710004, China. Electronic address:
Electrospun pectin nanofibers have emerged as a transformative advancement in biomaterials, offering remarkable potential across diverse biomedical and industrial applications. This review explores the synthesis, optimization, and versatile applications of electrospun pectin nanofibers, highlighting their unique properties, including biocompatibility, biodegradability, and adaptability for functionalization. Pectin's structural diversity, coupled with its ability to form hydrogels and interact with biological systems, makes it a promising candidate for wound healing, drug delivery, tissue engineering, and smart packaging.
View Article and Find Full Text PDFJ Med Internet Res
March 2025
Westmead Applied Research Centre, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.
Background: Conversational artificial intelligence (AI) allows for engaging interactions, however, its acceptability, barriers, and enablers to support patients with atrial fibrillation (AF) are unknown.
Objective: This work stems from the Coordinating Health care with AI-supported Technology for patients with AF (CHAT-AF) trial and aims to explore patient perspectives on receiving support from a conversational AI support program.
Methods: Patients with AF recruited for a randomized controlled trial who received the intervention were approached for semistructured interviews using purposive sampling.
Oncotarget
March 2025
Worldwide Innovative Network (WIN) Association - WIN Consortium, Chevilly-Larue, France.
The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed cancer treatment. Minimizing treatment not expected to benefit, and toxicity-including financial and time-are important goals of modern oncology.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!